Cellular Immunotherapy for Oncology 1 is under clinical development by GenoImmune Therapeutics Biotechnology and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cellular Immunotherapy for Oncology 1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cellular Immunotherapy for Oncology 1 overview
Cellular immunotherapy is under investigation for the treatment of advanced solid tumors including metastatic melanoma, colorectal cancer, gastric cancer, esophageal cancer, squamous cell carcinoma of the lung, cholangiocarcinoma, triple negative breast cancer, non-small cell lung cancer and renal cell carcinoma. It is administered as intravenous infusion in form of suspension. The therapy comprises of tumor specific antigen induced cytotoxic lymphocyte.
GenoImmune Therapeutics Biotechnology overview
GenoImmune Therapeutics Biotechnology is a biotechnology company that specialises in the therapy of tumour immune cells. The company is Headquartered in China.
For a complete picture of Cellular Immunotherapy for Oncology 1’s drug-specific PTSR and LoA scores, buy the report here.